StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Posted by Stephan Jacobs on Apr 17th, 2024

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report issued on Sunday. The firm issued a hold rating on the stock.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $2.08 on Friday. Can-Fite BioPharma has a 1 year low of $1.66 and a 1 year high of $3.33. The stock has a fifty day moving average of $2.16 and a two-hundred day moving average of $2.13. The firm has a market capitalization of $7.36 million, a PE ratio of -1.16 and a beta of 1.53.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. Equities research analysts predict that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Can-Fite BioPharma

Several institutional investors have recently modified their holdings of the company. Armistice Capital LLC acquired a new stake in shares of Can-Fite BioPharma in the first quarter valued at $756,000. Virtu Financial LLC purchased a new stake in shares of Can-Fite BioPharma during the second quarter valued at $52,000. Finally, Schechter Investment Advisors LLC purchased a new stake in shares of Can-Fite BioPharma during the fourth quarter valued at $44,000. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.